<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02240459</url>
  </required_header>
  <id_info>
    <org_study_id>FES-COG 1808</org_study_id>
    <nct_id>NCT02240459</nct_id>
  </id_info>
  <brief_title>A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment</brief_title>
  <official_title>A Double Blind, Randomized Four Way Cross Over Study to Compare the Effect of Fesoterodine 4mg and 8mg Once Daily and Oxybutynin 5mg Twice Daily After Steady State Dosing Versus Placebo on Cognitive Function in Subjects With Overactive Bladder, Over the Age of 75 Years With Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of fesoterodine at 4mg and 8mg doses
      versus a placebo and oxybutynin 5mg bid versus placebo on cognitive abilities in older people
      with overactive bladder and mild cognitive impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized placebo controlled, blinded four way cross over trial of the effect of
      medications used to treat overactive bladder on the cognition of older men and women with
      mild cognitive impairment. Each treatment phase is a week, with a weeks washout period before
      starting the next treatment. Cognitive testing is by way of a validated computer assisted
      battery of tests
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>continuity of attention</measure>
    <time_frame>1 and 4h post dose</time_frame>
    <description>Continuity of Attention:
Accuracy of responding in Choice Reaction Time task Percent Target Detection in Digit Vigilance task False Alarms in Digit Vigilance task</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cognitive function</measure>
    <time_frame>1 and 4h post last dose of study drug</time_frame>
    <description>includes the following domains of cognition
power of attention,
quality of working memory,
quality of episodic secondary memory,
speed of memory
Montreal Cognitive assessment score</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Fesoterodine 4mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fesoterodine 4mg oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fesoterodine 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fesoterodine 8mg in form of 2, 4mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxybutynin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oxybutynin immediate release, encapsulated 2, 5mg capsules daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsule, 2 per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fesoterodine 4mg</intervention_name>
    <description>7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning</description>
    <arm_group_label>Fesoterodine 4mg daily</arm_group_label>
    <arm_group_label>Fesoterodine 8mg</arm_group_label>
    <arm_group_label>oxybutynin</arm_group_label>
    <arm_group_label>placebo capsule</arm_group_label>
    <other_name>Toviaz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin</intervention_name>
    <description>5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo</description>
    <arm_group_label>Fesoterodine 4mg daily</arm_group_label>
    <arm_group_label>Fesoterodine 8mg</arm_group_label>
    <arm_group_label>oxybutynin</arm_group_label>
    <arm_group_label>placebo capsule</arm_group_label>
    <other_name>ditropan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes</description>
    <arm_group_label>Fesoterodine 4mg daily</arm_group_label>
    <arm_group_label>Fesoterodine 8mg</arm_group_label>
    <arm_group_label>oxybutynin</arm_group_label>
    <arm_group_label>placebo capsule</arm_group_label>
    <other_name>placebo capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fesoterodine 8mg</intervention_name>
    <description>2, 4mg fesoterodine capsules taken together in the morning</description>
    <arm_group_label>Fesoterodine 4mg daily</arm_group_label>
    <arm_group_label>Fesoterodine 8mg</arm_group_label>
    <arm_group_label>oxybutynin</arm_group_label>
    <arm_group_label>placebo capsule</arm_group_label>
    <other_name>Toviaz 8mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject is either male or female and â‰¥ 75 years of age.

          2. The subject has OAB as determined by ICS criteria

          3. The subject has mild cognitive impairment as determined by NIA criteria

          4. The subject is competent to give informed consent and perform the tasks associated
             with the study

          5. The subject has a body mass index (BMI) between 18.0 to 30.0 kg/m2 inclusive.

          6. Written informed consent has been obtained.

          7. The subject is available to complete the study.

          8. At training visits (visit 2): the subject has performed at or above the minimum level
             on at least one occasion for each individual task measure in cognitive function test
             training.

        Exclusion Criteria:

          1. The subject does not have OAB.

          2. The subject has either dementia or moderate to severe cognitive impairment at
             screening.

          3. The subject has probable clinical depression as determined by Geriatric Depression
             Scale (GDS) short form &gt;5 at screening.

          4. Subjects taking any cognitive enhancers (cholinesterase inhibitors or memantine).

          5. The subject has a history of allergy to the study drug(s), to any component of the
             dosage form or any other allergy, which, in the opinion of the Investigator,
             contraindicates their participation.

          6. The subject has any clinically significant abnormal heart rate or blood pressure
             measurements, at the screening visit, which, in the opinion of the Investigator,
             prevent safe participation in the study. (dBP&lt; 60mmHg or &gt; 90mmHg, sBP &lt; 95mmHg or &gt;
             160mmHg or HR &lt; 40bpm or &gt; 100bpm).

          7. Subjects with known history of urinary retention, severe gastrointestinal obstruction
             (including paralytic ileus or intestinal atony) or severe gastrointestinal conditions
             (including toxic megacolon or ulcerative colitis), myasthenia gravis, uncontrolled
             narrow angle glaucoma or shallow interior chamber or subjects deemed to be at risk for
             these conditions.

          8. Subjects undergoing haemodialysis or who have severe renal impairment.

          9. Subjects with severe hepatic impairment, defined as Child-Pugh grade IV.

         10. Subjects taking potent CYP 3A4 inhibitors which would, under normal circumstances,
             require adjustment of the dose of the test drugs.

         11. Subject has taken prescribed medication within 14 days prior to the first study day or
             over-the-counter medicine (including vitamins and herbal remedies) within 48 hours
             prior to the first study day, which in the opinion of the Investigator, will interfere
             with the study procedures or compromise safety.

         12. Subject has an average weekly alcohol intake of greater than 21 units (male) or 14
             units (female) within the 90 days prior to the study. 1 unit is 270cc of beer, 40cc of
             spirits or 125cc of wine.

         13. History of smoking more than 10 cigarettes (or the equivalent amount of tobacco) per
             day within the 90 days prior to the study.

         14. Subject has participated in any clinical study within the last 90 days.

         15. Any clinically significant abnormality following Investigator review of the pre study
             physical examination.

         16. Any clinical condition, which, in the opinion of the Investigator, would not allow
             safe completion of the study.

         17. Any subjects who, in the opinion of the investigator, may find it difficult to adhere
             to the provisions of treatment and observation specified in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian S Wagg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrian S Wagg, MD</last_name>
    <phone>780 492 5338</phone>
    <email>adrian.wagg@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saima Rajabali, MBBS</last_name>
    <phone>780 492 3700</phone>
    <email>srajabal@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Geriatric Medicine, Clinical Sciences Building, University of Alberta Hosp</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Wagg, MD</last_name>
      <phone>780 492 5338</phone>
      <email>adrian.wagg@ualberta.ca</email>
    </contact>
    <contact_backup>
      <last_name>Saima Rajabali, MBBS</last_name>
      <phone>780 492 3700</phone>
      <email>srajabal@ualberta.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Adrian S Wagg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saima Rajabali, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Gibson, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013 Jul;64(1):74-81. doi: 10.1016/j.eururo.2013.01.002. Epub 2013 Jan 11.</citation>
    <PMID>23332882</PMID>
  </reference>
  <reference>
    <citation>Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf. 2009 Nov;8(6):615-26. doi: 10.1517/14740330903260790.</citation>
    <PMID>19747069</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2014</study_first_submitted>
  <study_first_submitted_qc>September 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2014</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Adrian Wagg</investigator_full_name>
    <investigator_title>Research Chair in Healthy Aging</investigator_title>
  </responsible_party>
  <keyword>crossover study</keyword>
  <keyword>placebo controlled</keyword>
  <keyword>double blind</keyword>
  <keyword>overactive bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fesoterodine</mesh_term>
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Mandelic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

